Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma

@article{Woo2008UseOR,
  title={Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma},
  author={Chan-Wook Woo and Fei Tan and Hope Cassano and JungHwa Lee and Kwang Chul Lee and Carol J. Thiele},
  journal={Pediatric Blood \& Cancer},
  year={2008},
  volume={50}
}
MYCN amplification marks poor prognosis in neuroblastoma (NB) tumors. In evaluating the mechanisms by which retinoic acid (RA) or nerve growth factor (NGF) decrease cell number in MYCN amplified NB cells, we have identified a number of proteins whose expression either decreases (E2F, CDC2, CDK6, cyclin dependent kinase activity) or increases (p27) in association with a decrease in MYCN expression. However, it was still unclear which were MYCN dependent effects or not. 
MYCN oncoprotein targets and their therapeutic potential.
TLDR
The current evidence identifying the direct and indirect downstream transcriptional targets of MYCN from recent studies is discussed, with particular reference to how MYCN affects the cell cycle, DNA damage response, differentiation and apoptosis in neuroblastoma. Expand
MycN is a transcriptional regulator of livin in neuroblastoma.
TLDR
It is hypothesized that MycN is required for livin expression and that livin may counteract the proapoptotic effects of MycE, as well as induction of MyCN in neuroblastoma cells with low endogenous levels of HiscN and livin protein upregulated Livin expression. Expand
Overexpression of MYCN promotes proliferation of non-small cell lung cancer
TLDR
The finding suggested that MYCN might contribute to the progression of NSCLC by enhancing cell proliferation, and that targeting myelocytomatosis viral oncogene might provide beneficial effects for the clinical therapy of NSLI. Expand
The MYCN Protein in Health and Disease
TLDR
Targeting MYCN has been proposed as a therapeutic strategy for the treatment of these tumors and great efforts have allowed the development of direct and indirect MYCN inhibitors with potential clinical use. Expand
Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
TLDR
It is shown that MYCN suppresses the expression of Dickkopf-1 (DKK1) in both neuroblastoma cell lines SHEP-21N and SKNAS-NmycER, in which MYCN activity can be regulated, and suggests that MyCN might stimulate cell proliferation by inhibiting theexpression of DKK1. Expand
The MYCN oncogene is a direct target of miR-34a
TLDR
One important regulatory role of miR-34a in cell growth and MYCN suppression in neuroblastoma is demonstrated, and it is demonstrated that MYCN is a direct target ofmiR- 34a. Expand
Copy number defects of G1‐Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis
TLDR
The findings suggest that pharmacological inhibition of cell cycle genes might bear therapeutic promises for patients with high risk neuroblastoma. Expand
Clusterin (CLU) and its interacting proteins in cell signalling and neuroblastoma
TLDR
It is demonstrated that a direct interaction between intracellular CLU and HSP60 could play an important role in the regulation of NF-κB activity and neuroblastoma development. Expand
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
TLDR
This work discusses genes regulated by MYCN in neuroblastoma, with particular reference to p53, SKP2, and DKK3 and strategies that may be employed to target them. Expand
Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo.
TLDR
The data indicate that lentivirus vector-mediated silencing of MYCN in neuroblastoma cells could efficiently and significantly inhibit tumor growth both in vitro and in vivo. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 33 REFERENCES
Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2
TLDR
Retinoic acid decreases N-myc levels and induces cell cycle arrest in vitro and increases event-free survival in advanced stage NB patients and induces both N- myc-dependent and -independent mechanisms to minimize the degradation of p27 and arrest NB cell growth. Expand
Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma.
TLDR
It is reported that an "N-Myc-Id2 pathway" persists during late development of the nervous system and parallels the rising levels of active Rb in neuronal precursors withdrawing from the cell cycle and suggested that Id2 overexpression may be a better prognostic indicator than N-myc gene amplification in neuroblastoma. Expand
NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number
TLDR
Results indicate that the MAP kinase is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism, which is key to controlling growth and inducing differentiation in NB cells. Expand
Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer.
TLDR
The role of Myc in stimulating the G1/S transition of the cell cycle by regulating the levels and activity of cyclins, cyclin dependent kinases (cdk), cdk inhibitors and the pRb-binding transcription factor E2F is focused on. Expand
Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma
TLDR
It is reported that in the case of RA-induced differentiation of neuroblastoma cell lines, a decreased level of expression is detected within 6 h of treatment and precedes both cell-cycle changes and morphological differentiation. Expand
p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS–KCNR human neuroblastoma cell line
TLDR
Results indicate that changes in the level of p27Kip1 and its binding to G1 cyclin/Cdks may play a key role in RA induced growth arrest of NB cells. Expand
Targeted expression of MYCN causes neuroblastoma in transgenic mice
TLDR
It is shown that increases in MYCN dosage or deficiencies in either of the tumor suppressor genes NF1 or RB1 can augment tumorigenesis by the transgene, and the genetic events involved in the genesis of neuroblastoma can be tumorigenic in more than one chronological sequence. Expand
Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins
TLDR
It is shown that Id2–Rb double knockout embryos survive to term with minimal or no defects in neurogenesis and haematopoiesis, but they die at birth from severe reduction of muscle tissue. Expand
Contributions of Myc to tumorigenesis.
TLDR
This article will argue that current progress allows us to present testable hypotheses on how Myc affects specific properties of transformed cells. Expand
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
TLDR
It is demonstrated that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes, raising the possibility that transient in activation ofMYC may be an effective therapy for certain cancers. Expand
...
1
2
3
4
...